Published in Proc Natl Acad Sci U S A on August 31, 2006
The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol (2009) 2.79
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A (2007) 1.70
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J (2010) 1.42
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem (2009) 1.39
Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry (2009) 1.38
Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des (2009) 1.30
Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol (2011) 1.28
Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol (2010) 1.26
Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res (2010) 1.22
Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology. Nat Chem Biol (2012) 1.21
The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther (2009) 1.18
Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A (2012) 1.15
Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem (2012) 1.14
Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. J Med Chem (2012) 1.13
Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem (2011) 1.13
Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc Natl Acad Sci U S A (2008) 1.12
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis (2010) 1.10
Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem (2008) 1.10
Isofagomine induced stabilization of glucocerebrosidase. Chembiochem (2008) 1.09
High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One (2012) 1.07
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A (2011) 1.06
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Mol Genet Metab (2009) 1.06
Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS One (2011) 1.06
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. J Med Chem (2011) 1.05
Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. Mol Ther (2015) 1.04
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun (2008) 1.04
X-ray and biochemical analysis of N370S mutant human acid β-glucosidase. J Biol Chem (2010) 1.04
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis (2012) 1.02
The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder. Biochemistry (2011) 1.02
The role of saposin C in Gaucher disease. Mol Genet Metab (2012) 1.02
Two phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-glucocerebrosidase. Mol Biol Cell (2012) 1.00
What are pharmacological chaperones and why are they interesting? J Biol (2009) 0.99
Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells (2014) 0.98
β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem (2013) 0.97
Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis (2014) 0.92
Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol (2006) 0.87
Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. Mol Genet Metab (2012) 0.86
Production of active human glucocerebrosidase in seeds of Arabidopsis thaliana complex-glycan-deficient (cgl) plants. Glycobiology (2011) 0.86
The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem (2016) 0.85
Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S. J Biol Chem (2010) 0.84
A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics (2014) 0.82
Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. J Med Chem (2012) 0.82
Enzyme enhancers for the treatment of Fabry and Pompe disease. Mol Ther (2014) 0.82
Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism. J Biol Chem (2011) 0.82
Optimal therapy in Gaucher disease. Ther Clin Risk Manag (2010) 0.82
In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models. PLoS One (2009) 0.81
Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Aβ. Mol Psychiatry (2014) 0.80
Development of targeted therapies for Parkinson's disease and related synucleinopathies. J Lipid Res (2014) 0.80
Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Biochemistry (2011) 0.79
Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Hum Mol Genet (2015) 0.78
Fluorous iminoalditols: a new family of glycosidase inhibitors and pharmacological chaperones. Chembiochem (2010) 0.77
Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates. PLoS One (2015) 0.76
Engineering of GlcNAc-1-Phosphotransferase for Production of Highly Phosphorylated Lysosomal Enzymes for Enzyme Replacement Therapy. Mol Ther Methods Clin Dev (2017) 0.76
Molecular probes: Getting lucky in the lysosome. Nat Chem Biol (2010) 0.75
Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators. J Med Chem (2016) 0.75
Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener (2017) 0.75
Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol (2016) 0.75
Stabilization of glucocerebrosidase by active-site occupancy. ACS Chem Biol (2017) 0.75
Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat (2003) 12.88
Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med (1999) 3.11
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
The targeting of Lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane. J Cell Biol (1996) 2.32
Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest (1966) 2.01
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet (2005) 2.01
Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease. Cell Mol Life Sci (2006) 1.86
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A (2003) 1.57
A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J (2005) 1.53
Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease. Int J Biochem Cell Biol (2005) 1.50
Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol (2006) 1.45
Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J Biol Chem (2005) 1.45
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis (2004) 1.45
Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test (1997) 1.35
Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet (1993) 1.34
An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther (2005) 1.30
Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis (2004) 1.26
Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat (1998) 1.23
Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am J Hum Genet (1989) 1.19
Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis (2006) 1.16
Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur J Biochem (1987) 1.14
Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol (2005) 1.13
Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol (1997) 1.09
Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis (2005) 1.07
N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta (2004) 1.05
Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation). J Pathol (1999) 1.05
Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages. Mol Med (1995) 0.92
Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity. Blood (1997) 0.88
Expression of functional human acid beta-glucosidase in COS-1 and Spodoptera frugiperda cells. Enzyme (1989) 0.84
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
Autoinhibition of the ligand-binding site of GGA1/3 VHS domains by an internal acidic cluster-dileucine motif. Proc Natl Acad Sci U S A (2002) 1.19
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology (2004) 1.09
Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastroenterol Hepatol (2004) 1.04
Hypoxic activation of the PERK/eIF2α arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin Cancer Res (2013) 0.98
The DMAP interaction domain of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase is a substrate recognition module. Proc Natl Acad Sci U S A (2013) 0.98
Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus. AIDS (2005) 0.96
Mislocalization of phosphotransferase as a cause of mucolipidosis III αβ. Proc Natl Acad Sci U S A (2014) 0.96
AMPK regulates metabolism and survival in response to ionizing radiation. Radiother Oncol (2011) 0.94
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene (2009) 0.93
Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol (2006) 0.87
The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice. J Pathol (2010) 0.83
The costs of change: direct medical costs of solid organ transplantation in British Columbia, Canada, 1995-2003. Value Health (2008) 0.83
A devastating complication: duodenal perforation due to biliary stent migration. Surg Laparosc Endosc Percutan Tech (2008) 0.82
Numerical analysis of coronary artery bypass grafts: an over view. Comput Methods Programs Biomed (2012) 0.81
Assays of complex formation between RGS protein G gamma subunit-like domains and G beta subunits. Methods Enzymol (2002) 0.77
Separation, identification and quantification of tetrodotoxin and its analogs by LC-MS without calibration of individual analogs. Toxicon (2011) 0.77
Uptake of Gold Nanoparticles in Breathless (Hypoxic) Cancer Cells. J Biomed Nanotechnol (2015) 0.76
New pathway links γ-secretase to inflammation and memory while sparing notch. Ann Neurol (2011) 0.76
Topical mechlorethamine restores autoimmune-arrested follicular activity in mice with an alopecia areata-like disease by targeting infiltrated lymphocytes. J Invest Dermatol (2003) 0.76
Graft-artery junctions: design optimization and CAD development. Methods Mol Biol (2012) 0.75
The Washington University Medical Scientist Training Program. Mo Med (2004) 0.75
Is a liver biopsy necessary? Investigation of a suspected hepatocellular carcinoma: a pictorial essay of hepatocellular carcinoma and the revised American Association for the Study of Liver Disease criteria. Can Assoc Radiol J (2011) 0.75